Key result
The novel R1905X DYSF founder mutation in homozygosity produced 3 different dysferlinopathy phenotypes without intrafamilial heterogeneity in all 8 evaluated patients from Spain.
Population
8 patients with dysferlinopathy from 5 unrelated families
Design
Case_series
Authors
Loading...
Variable phenotypes in this founder cohort warrant cautious prognosis counseling; leaves open modifier identification in homogeneous dysferlinopathy patients.
Observational (n=8)
The identification of the R1905X DYSF founder mutation in a Spanish population highlights phenotypic variability in dysferlinopathies and provides a homogeneous cohort for studying modifying factors.
Vílchez et al. (2005) conducted an observational in dysferlinopathy (n=8). R1905X mutation in the DYSF gene was evaluated on Clinical phenotypes. The novel R1905X DYSF founder mutation in homozygosity produced 3 different dysferlinopathy phenotypes without intrafamilial heterogeneity in all 8 evaluated patients from Spain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: